Stock CYP CYNATA THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Cynata Therapeutics Limited

Equities

CYP

AU000000CYP7

Delayed Australian S.E.
Other stock markets
 10:23:01 2024-04-18 pm EDT 		5-day change 1st Jan Change
0.205 AUD -2.38% Intraday chart for Cynata Therapeutics Limited +10.81% +64.00%
Apr. 08 Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial CI
Apr. 08 Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cynata Therapeutics Limited Completes Patient Enrolment in CYP-006TK Diabetic Foot Ulcer Clinical Trial
CI
Cynata Therapeutics Concludes Patient Enrolment in Diabetic Foot Ulcer Wound Dressing Product Trial
MT
Cynata Therapeutics Receives EU Approval for CYP-001 Phase 2 Trial
MT
Cynata Therapeutics Doses First Patient in Phase Two Trial of Cellular Therapy; Shares Rise 5%
MT
Cynata Therapeutics Limited Announces Updates on Phase 2 Clinical Trial of CYP-001
CI
Cynata Therapeutics Names Chief Business Officer; Shares Plunge 14%
MT
Cynata Therapeutics Limited Announces Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial
CI
Cynata Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
Cynata Therapeutics Expects Initial Results in Diabetic Foot Ulcer Topical Wound Dressing Trial in Q1 2024
MT
Cynata Therapeutics Completes Recruitment for Phase Three Osteoarthritis Trial
MT
Cynata Therapeutics Secures Approval in Turkey for Phase 2 Trial of HR-aGvHD; Shares Jump 9%
MT
Cynata Therapeutics Receives AU$2.3 Million R&D Tax Rebate
MT
Acute Respiratory Distress Syndrome Pipeline | Clinical Trials and Key Companies
AQ
Cynata Therapeutics Secures Clearance to Advance Phase Three Knee Pain Trial
MT
Cynata Therapeutics Limited Announces Resignation of David Atkins as Director
CI
Cynata Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Cynata Therapeutics Opens Enrollment for Phase Two Cell Therapy Trial
MT
Cynata Therapeutics Taps COO for CEO/Managing Director Role; Shares Down 4%
MT
Cynata Therapeutics Limited Announces Management Appointments
CI
Cynata Therapeutics Limited Announces Chief Executive Officer Changes
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYP Stock
  4. News Cynata Therapeutics Limited